Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941844 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
A Phase 3 study of Major Depressive Disorder, sponsored by Definium Therapeutics US.
- Active
- Registry status
- Phase 3
- Development phase
- 149
- Enrollment target
- 20
- Study locations
NCT06941844 is a Phase 3 study of Major Depressive Disorder that is active but no longer recruiting, run by Definium Therapeutics US. The registered enrollment target is 149 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06941844, a Phase 3 study of Major Depressive Disorder, is active but no longer recruiting, sponsored by Definium Therapeutics US.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 149 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MM120 (LSD D-Tartrate)
Study Locations (20)
Florida
- Clinical Neuroscience Solutions, Inc - Jacksonville
- Clinical Neuroscience Solutions, Inc - Orlando
- Charter Research - Orlando
Arkansas
- Preferred Research Partner - Fayetteville
- Preferred Research Partners, Inc - Little Rock
California
- Kadima Neuropsychiatry Institute - La Jolla
- Psychedelic Science Institute - Santa Monica
Massachusetts
- Adams Clinical Boston - Boston
- Adams Clinical - Watertown
New York
- Adams Clinical Harlem - New York
- Columbia - New York State Psychiatric Institute - New York
Ohio
- Neuro-Behavioral Clinical Research - Canton
- University of Cincinnati - Cincinnati
Colorado
- Mountain View Clinical Research, Inc - Denver
Illinois
- Uptown Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06941844
The ClinicalTrials.gov registry entry for NCT06941844 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower). The listed sponsor is Definium Therapeutics US, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06941844 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT06941844 about?
NCT06941844 is a clinical study titled "A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)". A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
What is the current status of trial NCT06941844?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 149 participants. The study started on 2025-04-14. Estimated completion is 2027-05.
What conditions does trial NCT06941844 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT06941844?
The interventions under investigation include: Placebo (OTHER), MM120 (LSD D-Tartrate) (DRUG).
Who is sponsoring clinical trial NCT06941844?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941844 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.